Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01,...
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...
VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary...
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in...
48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting with FDA for MASH Program Scheduled in Fourth Quarter Executive Leadership Strengthened...
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline...
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...
Oral presentation to highlight 24-week efficacy and safety data Poster to feature results of AI-based analyses of liver fibrosis reduction GAITHERSBURG, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) --...